

OBESE PATIENTS WITH DIABETES MELITTUS TYPE II (T2DM). SLEEVE GASTRECTOMY OR ONE ANASTOMOSIS GASTRIC BYPASS SHOULD BE THE TREATMENT OF CHOICE? RESULTS OF A SINGLE-CENTER STUDY IN GREECE

<u>Vrakopoulou Gavriella Zoi</u>¹; Theodoropoulos Charalampos¹; Kalles Vassilios¹; Matiatou Maria¹; Kostopoulou Fotini²; Zografos George K.¹; Leandros Emmanouil¹; Albanopoulos Konstantinos¹


1) Background: The number of individuals with T2DM has increased rapidly over the last decades with the vast majority of them being obese. Weight-loss surgery has proven itself effective, with laparoscopic sleeve gastrectomy (LSG) being the most popular bariatric operation worldwide over the last decades. Meanwhile, laparoscopic one anastomosis gastric bypass (OAGB) is gaining popularity among an increasing number of surgeons. The aim of this study was to evaluate and compare the efficacy of these two weight-reducing operations on diabetic T2DM control obese for patients.


Preoperatively	LSG	OAGB	
N (patients)	28	25	
Age (years)	45.9 ± 7.5	46.6 ± 7.9	NS
Sex Distribution	12♂ (42.9%) / 16♀ (57.1%)	10♂ (40.0%) / 15♀ (60.0%)	NS
IBW (kg) ¹	73.7 ± 9.7	73.4 ± 8.5	NS
TBW (kg) ²	153.8 ± 30.4	155.7 ± 38.0	NS
BMI (kg/m ²) ³	52.2 ± 8.6	52.9 ± 10.9	NS
1st Dgr Diabetics (pts)	19 (67.9%)	15 (60.0%)	NS
HbA1c (%)	7.1 ± 1.2	7.8 ± 2.0	NS
IDDM (pts) ⁴	6 (21.4%)	8 (32.0%)	0.04
>1 Antidiabetic Agents	8 (28.6%)	9 (36%)	NS


2) Methods: This is a single-centre (single-surgeon) study of a tertiary hospital, certified as center of Excellence for Bariatric and Metabolic Surgery. The data were collected prospectively and analyzed retrospectively. Included were T2DM obese patients who underwent LSG (Group A) and OAGB (Group B) from September 2011 to October 2015. Patient demographic characteristics, weight, co-morbidities, HbA1c, anti-diabetic medications, and changes or discontinuation of treatment were recorded at baseline, 1, 3, 6, 12, 18, 24 and 36 months. All patients were followed-up for at least 36 months. The primary outcome was remission of T2DM (HbA1c <6.5% without glycemic therapy). Secondary measures included weight and changes of lifestyle related to the glucose levels.

3) Results: In a total of 900 patients submitted to LSG or OAGB during the study period, 53 T2DM obese patients have been followed-up for a minimum period of three years.

Follow-up (36 months)	LSG	OAGB	
N (patients)	28	25	
TBW	97.7 ± 18.8	90.7 ± 17.6	NS
BMI $(Kg/m^2)^2$	33.8 ± 6.5	31.4 ± 6.1	NS
$\Delta BMI (kg/m^2)$	18.4 ± 6.3	19.4 ± 4.7	NS
%EWL ³	79.8 ± 14.5	93.3 ± 16.0	0.00
HbA1c (%)	5.8 ± 0.5	5.2 ± 0.8	
ΔHbA1c (%)	1.4 ± 1.5	2.7 ± 2.1	0.02
Treatment Discont. (pts)	10 (35.7%)	22 (88.0%)	<0.0
Postop Month of Discont.	1st (70%)	1st (81.8%)	
Hypoglycemic Episodes	7 (25.0%)	8 (32.0%)	NS







4) Conclusion: OAGB seems to be a more efficient method for the treatment of Diabetes Mellitus Type II in obese patients. In comparison to LSG, OAGB is more effective in %EWL and improvement of glycemic control, with almost immediate

resolution of diabetes, as well as long-term weight loss.

Disclosure: Vrakopoulou Gavriella Zoi: No conflicts; Theodoropoulos Charalampos: No conflicts; Kalles Vassilios: No conflicts; Matiatou Maria: No conflicts; Kostopoulou Fotini: No conflicts; Zografos George K.: No conflicts; Leandros Emmanouil: No conflicts; Albanopoulos Konstantinos: No conflicts

¹ Laparoendoscopic Unit, Hippokration General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece.

² Department of Anesthesiology, Hippocration General Hospital, Athens, Greece.